잠시만 기다려 주세요. 로딩중입니다.

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data

Cancer Research and Treatment
2018년 50권 4호 p.1149 ~ p.1163
김민기 ( Kim Min-Ki ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery

 ( Won Dae-Youn David ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery
박선민 ( Park Sun-Min ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery
김대중 ( Kim Tae-Jung ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery
김성용 ( Kim Sung-Ryong ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery
오성택 ( Oh Seong-Taek ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Surgery
손승국 ( Sohn Seung-Kook ) - Health Insurance Review and Assessment Service
강미연 ( Kang Mi-Yeon ) - Health Insurance Review and Assessment Service
이인규 ( Lee In-Kyu ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Surgery

Abstract

Purpose: Debates exist regarding the effectiveness of adjuvant chemotherapy for stage II colon cancer. This study aimed to investigate the current status of adjuvant chemotherapy and its impact on survival for Korean stage II colon cancer patients by analyzing the National Quality Assessment data.

Materials and Methods: A total of 7,880 patientswho underwent curative resection for stage II colon adenocarcinoma between January 2011 andDecember 2014 in Koreawere selected randomly as evaluation subjects for the quality assessment. The factors that influenced overall survival were identified. The high-risk group was defined as having at least one of the following: perforation/obstruction, lymph node harvest less than 12, lymphovascular/perineural invasion, positive resection margin, poor differentiation, or pathologic T4 stage.

Results: The median follow-up period was 38 months (range, 1 to 63 months). Chemotherapy was a favorable prognostic factor for either the high- (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.38 to 0.59; p < 0.001) or low-risk group (HR, 0.74; 95% CI, 0.61 to 0.89; p=0.002) in multivariate analysis. This was also the case in patients over 70 years of age. The hazard ratio was significantly increased as the number of involved risk factors was increased in patients who didn’t receive chemotherapy. Adding oxaliplatin showed no difference in survival (HR, 1.36; 95% CI, 0.91 to 2.03; p=0.132).

Conclusion: Adjuvant chemotherapy can be recommended for stage II colon cancer patients, but the addition of oxaliplatin to the regimen must be selective.

키워드

원문 및 링크아웃 정보
 
등재저널 정보
SCI(E) MEDLINE 학술진흥재단(KCI) KoreaMed 대한의학회 회원 
주제코드
주제명
(Target field)
연구대상
(Population)
연구참여
(Sample size)
대상성별
(Gender)
질병특성
(Condition Category)
연구환경
(Setting)
연구설계
(Study Design)
연구기간
(Period)
중재방법
(Intervention Type)
중재명칭
(Intervention Name)
키워드
(Keyword)
유효성결과
(Recomendation)
연구비지원
(Fund Source)
근거수준평가
(Evidence Hierarchy)
출판년도
(Year)
참여저자수
(Authors)
대표저자
(1st Authors)
Doi
KCD코드
ICD 03
건강보험코드